Loading
Life sciences · Journal article
Future Science Oa · July 15, 2026
Raises a question worth testing. It does not answer one.
This mechanistic study identifies USP14 as an overexpressed deubiquitinase in head and neck squamous cell carcinoma that directly stabilizes the actin-remodeling protein CFL2 by preventing its proteasomal degradation. The work establishes a novel USP14–CFL2 regulatory axis in cell lines and xenograft models, with clinical correlations showing both proteins are overexpressed in HNSCC tissues and associate with poor prognosis, but does not include clinical trial data or therapeutic outcome evidence.
Mechanistic in vitro and in vivo study with translational biomarker analysis. HNSCC tissues from 8 patients (western blot) and 79 patients (immunohistochemistry) treated at Third Affiliated Hospital of Sun Yat-sen University between June 2020 and June 2022; HNSCC cell lines; mouse xenograft models.. Intervention: CRISPR/Cas9-mediated USP14 knockout or USP14 overexpression in HNSCC cell lines; mouse xenograft tumor models derived from USP14-knockout or control cells. Compared with: Wild-type or control cell lines; vehicle or normal adjacent epithelial tissue controls. Third Affiliated Hospital of Sun Yat-sen University and Jinan University, Guangzhou, China.
USP14 is significantly overexpressed in HNSCC tissues and correlates with advanced N stage and poor prognosis CRISPR/Cas9-mediated USP14 knockout suppresses HNSCC cell proliferation, migration, and tumor growth in vitro and in vivo USP14 directly binds to and deubiquitinates CFL2, protecting it from proteasomal degradation and enhancing its stability
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This work identifies USP14 and CFL2 as candidate biomarkers and potential therapeutic targets in HNSCC, but the evidence is mechanistic and preclinical. Clinical validation through patient trials and assessment of USP14 or CFL2 inhibition as a therapeutic strategy are required before any practice change.
This is mechanistic in vitro and in vivo work identifying a novel protein–protein interaction and biochemical pathway, without clinical outcome data or patient treatment trials, establishing a candidate therapeutic axis rather than practice-changing evidence.
As stated by the source record.
Quoted from the source exactly as published.
This work identifies USP14 and CFL2 as candidate biomarkers and potential therapeutic targets in HNSCC, but the evidence is mechanistic and preclinical. Clinical validation through patient trials and assessment of USP14 or CFL2 inhibition as a therapeutic strategy are required before any practice change.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Aim. To identify novel substrates of USP14 and elucidate the molecular mechanisms by which USP14 promotes head and neck squamous cell carcinoma (HNSCC) progression.Materials and methods. USP14 expression patterns were examined in HNSCC tissues and cell lines. Functional effects were assessed using genetic knockout and overexpression models in vitro and in vivo. USP14-CFL2 interactions were evaluated by co-immunoprecipitation and GST pull-down assays. Deubiquitination activity was measured in vitro. Transcriptomic analysis and bioinformatics were used to identify downstream pathways and clinical relevance.Results. USP14 was significantly overexpressed in HNSCC and correlated with poor prognosis. Genetic knockout of USP14 markedly suppressed HNSCC cell proliferation, migration, and tumor growth, while USP14 overexpression exerted opposite effects. Mechanistically, we identified CFL2 as a novel substrate of USP14; USP14 directly interacted with and deubiquitinated CFL2, thereby enhancing its stability by preventing proteasomal degradation. Clinically, CFL2 was also overexpressed in HNSCC and its elevated levels correlated with reduced overall survival. Functionally, CFL2 overexpression significantly rescued the anti-tumor effects of USP14 knockout, including impaired cell proliferation and migration.Conclusion. In summary, our findings identify a novel USP14-CFL2 regulatory axis and establish USP14 as a critical promoter of HNSCC progression, acting through CFL2 deubiquitination and stabilization.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.